Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.

Inhaled treprostinil reduces lung function decline and clinical worsening in patients with idiopathic pulmonary fibrosis over 52 weeks.

• Why it matters: IPF is a progressive disease with limited treatment options, and effective therapies are urgently needed to slow lung function decline and improve patient outcomes.
• What they did: A phase 3, double-blind trial randomly assigned 593 patients to inhaled treprostinil or placebo, measuring changes in forced vital capacity (FVC) and clinical events over a year.
• The result: Treprostinil led to a smaller FVC decline (-49.9 ml vs. -136.4 ml) and fewer clinical worsening events, although cough was common, and discontinuation rates were higher with treprostinil.